Mindray(SZ:300760) Cai Jing Wang·2025-11-28 07:16Core Viewpoint - The announcement from Mindray Medical (300760) highlights the confidence of its chairman, Li Xiting, in the company's intrinsic value and future development through his recent share purchase and subsequent buyback plan [1] Group 1: Share Purchase Details - Li Xiting completed his first share purchase on November 27, acquiring 152,340 shares at an average price of 196.862 yuan per share, totaling approximately 29,999,930.80 yuan (around 29.99 million yuan) [1] - Prior to this purchase, Li Xiting did not hold shares directly but controlled 26.98% of the company through the controlling shareholder Smartco Development, along with 24.49% controlled by his concerted actor Xu Hang, totaling 51.47% control [1] - After the purchase, Li Xiting's direct shareholding increased to 152,340 shares, slightly raising the total control ratio to 51.48%, maintaining stable control over the company [1] Group 2: Future Buyback Plan - Li Xiting plans to continue purchasing shares over the next six months, with a total buyback amount of 200 million yuan (including the initial purchase amount) [1] - The funding for this buyback will come from Li Xiting's personal funds, with no set price range for the purchases, allowing for flexibility based on market trends [1] - The shares acquired during this buyback will be locked for six months post-completion, and there will be no selling of shares during the buyback period or within the legal timeframe, ensuring compliance with regulations against insider trading and short-term trading [1]